Neonatal Hemochromatosis (Gestational Alloimmune Liver Disease)

Definition And Pathophysiology

  • Single most common cause of acute liver failure during first month of life.
  • Not a primary iron overload disease; secondary to severe fetal liver injury.
  • Driven by gestational alloimmune liver disease (GALD) in nearly all cases.
  • Maternal immune system sensitized to unknown fetal hepatocyte cell surface antigen.
  • Maternal immunoglobulin G (IgG) crosses placenta, binding fetal liver antigens.
  • Activates terminal complement cascade, forming C5b-9 membrane attack complex.
  • Induces massive hepatocyte injury and death.
  • Fetal liver injury impairs synthesis of iron regulatory and transport proteins (hepcidin).
  • Impaired regulation causes excess non-transferrin-bound iron.
  • Results in extrahepatic siderosis dictated by normal tissue capacity to import non-transferrin-bound iron.
  • High recurrence rate in families; >90% probability subsequent infants affected.

Clinical Manifestations

  • Presents at birth or within first few days of life.
  • Prematurity or intrauterine growth restriction common.
  • Jaundice, hypoglycemia, severe coagulopathy refractory to vitamin K.
  • Hypoalbuminemia.
  • Transaminases normal or mildly elevated, out of proportion to degree of liver failure.

Diagnostic Evaluation

  • High serum ferritin, elevated alpha-fetoprotein, raised iron saturation.
  • Extrahepatic iron deposition spares reticuloendothelial system.
  • Magnetic resonance imaging (MRI) demonstrates extrahepatic siderosis in pancreas, myocardium, or thyroid follicles.
  • Salivary gland/buccal submucosal biopsy confirms extrahepatic siderosis safely.
  • Liver biopsy reveals acute and chronic inflammation, fibrosis, cirrhosis, absent surviving hepatocytes.
  • Positive immunohistochemical staining for C5b-9 membrane attack complex on liver tissue.

Management And Prevention

Acute Postnatal Management

  • Antioxidant cocktail (N-acetylcysteine, selenium, desferrioxamine, prostaglandin E1, vitamin E) historically utilized for iron chelation/free radical scavenging; lacks proven benefit.
  • Intravenous immunoglobulin (IVIG) administration (1 g/kg) combined with exchange transfusion.
  • Exchange transfusion removes circulating maternal IgG.
  • IVIG/exchange transfusion significantly decreases need for liver transplantation.
  • Liver transplantation indicated for failed medical management.

Antenatal Prevention

  • Indicated for mothers with previously affected pregnancy.
  • Maternal IVIG administration (1 g/kg bodyweight weekly).
  • Initiated at 18 weeks gestational age; continued until end of gestation.
  • Decreases GALD in developing fetus; achieves milder phenotypic expression and 100% infant survival.

Hereditary And Juvenile Hemochromatosis

Pathophysiology Of Iron Transport

  • Normal intestinal iron absorption utilizes heme carrier protein 1 (HCP1) and divalent metal transporter 1 (DMT1) for apical uptake.
  • Iron efflux at basolateral enterocyte membrane mediated by ferroportin 1.
  • Hepatic hormone hepcidin controls plasma iron levels.
  • Hepcidin binds ferroportin, inducing phosphorylation, internalization, and degradation of iron exporter.
  • Hepcidin deficiency causes unchecked iron absorption and systemic iron overload.

Genetic Classification

DisorderGenetic DefectPathogenetic Mechanism
Classic HemochromatosisHFE gene variants (Cys282Tyr, His63Asn, Ser65Cys).Reduces endocytic uptake of diferric transferrin by transferrin receptor-1 at basolateral membrane.
Juvenile Hemochromatosis (Type 2B)Hepcidin gene mutations.Primary hepcidin deficiency eliminates negative regulation of ferroportin, causing massive iron influx.
Hemochromatosis Type 4Ferroportin 1 gene mutations.Autosomal dominant defect in iron exporter function.

Clinical Manifestations

  • Rare presentation in pediatric population.
  • Progressive iron accumulation causes multiorgan dysfunction.
  • Associated with bronze diabetes and arthropathy.
  • Hepatomegaly, potential progression to cirrhosis.

Diagnostic Evaluation

  • Markedly elevated serum ferritin and transferrin saturation.
  • Hepatic iron content elevated on biopsy.
  • HFE genetic testing confirms classic variants.

Differential Diagnosis Of Neonatal Liver Failure

Differentiating GALD/Neonatal Hemochromatosis from other acute neonatal liver failure etiologies requires careful biochemical correlation.

EtiologyTransaminases (IU/L)Coagulopathy (INR)Ferritin (ng/mL)
Gestational Alloimmune Liver Disease (GALD)Normal/mild increase (<100)Significant increase800 - 7,000
Hemophagocytic Lymphohistiocytosis (HLH)Moderate/significant increase (>1,000)Moderate/significant increaseSignificant increase (>20,000)
Mitochondrial HepatopathyModerate increase (100 - 500)Moderate/significant increaseVariable
Viral InfectionSignificant increase (>1,000)Moderate/significant increaseVariable
Ischemic HepatitisSignificant increase (>1,000 - 6,000)Moderate/significant increaseVariable